ImmuneOncia Therapeutics, Inc. (KOSDAQ:424870)
South Korea flag South Korea · Delayed Price · Currency is KRW
3,440.00
+45.00 (1.33%)
At close: Aug 11, 2026

ImmuneOncia Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
59.44111.21654.541107,73335.95
Revenue Growth
-91.58%-83.01%495.04%-98.58%21413.29%1337.90%
Gross Profit
45.6298.26643.4292.917,71628.15
Operating Income
-29,235-28,005-12,599-11,797-15,073-11,896
Net Income
-28,544-27,363-5,6878,864-3,492-60,490
Earnings Per Share
-391.29-389.65-101.00169.00-67.00-1302.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
18,99423,43811,32625,95726,73042,320
Total Debt
55.769.5395.06136.94122.97314.63
Net Cash (Debt)
18,93823,36811,23125,82026,60742,005
Net Cash Growth
68.62%108.06%-56.50%-2.96%-36.66%103.58%
Net Cash Per Share
259.61332.76199.46492.28510.53904.13

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-26,298-22,775-14,670-8,337-15,301-1,976
Capital Expenditures
-348.16-329.97-86.87-428.43-36.21-101.34
Free Cash Flow
-26,647-23,105-14,757-8,766-15,337-2,078
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
76.74%88.36%98.30%84.47%99.77%78.31%
Operating Margin
-49179.97%-25182.04%-1924.80%-10724.51%-194.91%-33093.66%
Pretax Margin
-48017.87%-24605.12%-868.86%8058.20%-45.15%-168272.99%
Profit Margin
-48017.87%-24605.12%-868.86%8058.20%-45.15%-168272.99%
FCF Margin
-44825.92%-20776.54%-2254.59%-7968.93%-198.32%-5779.96%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
5281.838683.03----